Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Change in Accured Expenses (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Change in Accured Expenses for 11 consecutive years, with -$603224.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 67.24% to -$603224.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $345671.0, a 135.09% increase, with the full-year FY2024 number at $8761.0, up 101.22% from a year prior.
  • Change in Accured Expenses was -$603224.0 for Q3 2025 at Marker Therapeutics, down from $177803.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q2 2022 to a low of -$4.0 million in Q1 2022.
  • A 5-year average of $106461.3 and a median of $111171.0 in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 960.07% in 2024; the steepest drop was 977.65% in 2024.
  • Marker Therapeutics' Change in Accured Expenses stood at $1.4 million in 2021, then plummeted by 173.65% to -$1.0 million in 2022, then surged by 45.77% to -$558826.0 in 2023, then skyrocketed by 177.84% to $434978.0 in 2024, then tumbled by 238.68% to -$603224.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Change in Accured Expenses are -$603224.0 (Q3 2025), $177803.0 (Q2 2025), and $336114.0 (Q1 2025).